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Abstract
Background: The present paper is intended to be a practical 
guide organized by statements describing methods to re-
duce risks related to CT examinations in cancer patients. 
Methods: A panel of radiologists, oncologists and nephrolo-
gists were selected based on their publication records in the 
field and expertise. Ten clinical questions, which were de-
rived from clinical needs and an integration of all the commit-
tee members’ suggestions, were stated. The modified Delphi 
approach was used; it involved a detailed literature review 
and the collective judgement of experts, including electronic 
and face-to-face discussions. Results: Ten statements were 
derived from expert opinions based on the current literature, 
recently developed guidelines and technological advance-
ments. Each statement is discussed in a short paragraph re-
porting the current key evidence. Conclusion: This paper ad-
dresses the clinical implications of performing numerous CT 
examinations in patients with cancer, providing clinicians 
with information regarding methods to reduce risk factors in 
this patient population. © 2018 S. Karger AG, Basel
Background
Cancer represents the second most important cause of 
death and morbidity in Europe, with more than 3.7 mil-
lion new cases and 1.9 million deaths reported each year. 
In the United Kingdom, the number of cancer survivors 
has increased by 3% per annum [1]. Overseas, the 
 American Cancer Society, in collaboration with the Na-
tional Cancer Institute, estimates that more than 15.5 mil-
lion cancer survivors are living in the United States today, 
and that number is expected to increase to 20 million by 
2026 [2]. Consequently, over the next decade, the number 
of cancer survivors is expected to increase worldwide. 
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The growing number of patients with cancer and can-
cer survivors results from several factors. First, advances 
in the scientific understanding and the precision of med-
ical treatments have improved patient outcomes and 
quality of life. Second, improvements in early detection 
have simplified cancer treatment. Third, the ageing popu-
lation may be the most influential factor affecting the in-
creasing number of these patients.
Despite the variability related to cancer type, the median 
age of patients at the time of cancer diagnosis is 65 years old. 
Of the 47% of cancer survivors, almost half are 70 years old 
or older, and only 5% are younger than 40 [2]. An aging 
population will increase the number of patients whose can-
cer will be complicated by other chronic diseases. For these 
reasons, the management of patients with cancer will be 
particularly challenging, and a panel of specialists with dif-
ferent areas of expertise will play a crucial role.
Patients with cancer usually undergo several imaging 
examinations that generally require the intravascular ad-
ministration of contrast medium (CM), particularly CT. 
One of the most subtle but relevant risks related to iodin-
ated contrast agents is acute kidney injury (AKI), which 
occurs in 2.3% of all CT examinations. The risks of devel-
oping this complication are compounded by several pa-
tient conditions, such as advanced age, dehydration and 
coadministration of nephrotoxic chemotherapeutic 
drugs. Primary care physicians and all specialists involved 
in managing patients with cancer should have a basic un-
derstanding of these risks and should be aware of recent 
developments in CM and CT scanners that can poten-
tially reduce them. 
In this article, we review the definition, epidemiology, 
possible mechanisms and risk factors for contrast-induced 
AKI (CI-AKI) and provide recommendations for prevent-
ing this potentially life-threatening complication. There-
fore, the aim of the present study is to provide a practical 
overview of the most common risk factors to be considered 
in patients with cancer before performing a contrast-en-
hanced CT (CECT) examination while providing an evi-
dence-based approach to reduce cancer risks related to 
CM and radiation exposure during medical imaging.
Methods
A panel of radiologists, oncologists and nephrologists chaired 
by A.L., C.R., and L.D.M. were selected based on their publication 
records in the field, expertise and geographical location to ensure 
an appropriate representation across the country. Research fel-
lows were considered for an appointment to the committee to help 
with some of the tasks, such as researching published studies and 
drafting documents. All the invited members are listed as con-
tributors. Demographics of all experts involved are reported in 
online supplementary Appendix 1 (see www.karger.com/
doi/10.1159/000486821). The specific role of all members in this 
project is reported in the Author Contribution Section.
A modified Delphi approach was used; it involved a detailed 
literature review and the collective judgement of experts, including 
electronic and face-to-face discussions. Under the direction of the 
coordinating team (D.B., A.L., L.D.M., and C.R.), the committee 
produced the initial questions containing all items for which a con-
sensus statement is planned. The draft questionnaire was sent to 
all members and modified based on feedback from all committee 
members. The coordinating team convened 3 working groups, one 
composed of radiologists, 1 group of nephrologists and 1 group of 
oncologists, and allocated the key questions to these task forces ac-
cording to the subspecialities of the members involved. 
Each working group performed a systematic literature search to 
prepare evidence-based statements for their assigned key ques-
tions. Medline, EMBASE and other databases were searched, in-
cluding the following minimum search terms: computed tomogra-
phy, oncology patients, CT acquisition protocol, contrast enhance-
ment, low-dose CT scanner, contrast media osmolality, CI-AKI, 
renal function, biomarkers, radiation exposure and risk evaluation. 
All articles investigating risks correlated to CM and radiation 
exposure in patients affected by any cancer were selected by in-
specting the title and abstract. Articles reporting risks related to 
gadolinium-based contrast media were excluded. After further ex-
ploring the content, each task force summarized the included ar-
ticles in a table of evidence. The final search results were circulated 
to all committee members, along with full abstracts and full papers. 
Working groups were free to update the literature search at their 
discretion. Studies published up to November 2016 were included.
Each task force prepared statements answering their assigned 
key questions. The statements were subsequently discussed and 
voted on during a face-to-face meeting of the entire group held on 
November 9, 2016. In January, 2017, a draft prepared by the coor-
dinating team (D.B., A.L., L.D.M., and C.R.) was sent to all group 
members for comments. After definitive approval of the final draft, 
the language of the manuscript was reviewed and then submitted 
to the journal. Due to the practical intent of the current study and 
the lack of specific relevant evidence for these topics, no specific 
grading system was used.
Results
Clinical questions, which were derived from clinical 
needs and an integration of all the committee members’ 
suggestions, are stated below. The statements and recom-
mendations appear in italics. 
Is There an Increased Risk of AKI in Patients with 
Cancer? 
The incidence of AKI in patients with cancer ranges 
from 12 to 17%, and it is higher than the incidence observed 
in patients without cancer (5–8%). Risk factors include the 
type of cancer, comorbidities, co-treatment with FANS/fu-
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rosemide, antibiotics, chemotherapy and CM administra-
tion. Among drugs commonly used for chemotherapy and 
targeted therapy, an increased risk of AKI has been docu-
mented in patients treated with bevacizumab, pemetrexed, 
cetuximab, ifosfamide and the platinum derivative cispla-
tin. Specific cancer locations (esophagus, kidney, liver, 
pancreas, craniopharyngeal duct, heart/mediastinum and 
uterus) and cancer types (lymphoma, leukemia, mixed 
lymphosarcoma, multiple myeloma) correlate with an in-
creased risk of AKI.
Should an Iodate CM Injection be Considered a 
Relevant Risk Factor for AKI?
Iodate CM is a risk factor for AKI. The risk for AKI as-
sociated with CM (OR 4.55) is higher than the risk observed 
for other risk factors, such as diabetes, chemotherapy, hy-
ponatremia and antibiotic use. A short time span between 
chemotherapy administration and CM injection is associ-
ated with an increased risk of AKI.
Is the Use of Iso-Osmolar Contrast Media Preferable 
to the Use of Low Osmolar Contrast Media as a 
Strategy to Prevent CI-AKI in Patients with Cancer?
The use of CM with the lowest osmolarity is advisable, 
particularly in high-risk patients. Patients with cancer must 
be considered as a high-risk group, and Iso-Osmolar Con-
trast Media (IOCM) should be considered the first choice, 
particularly if the patients are affected by at least one of the 
following conditions: intra-arterial injection, diabetes mel-
litus, liver diseases, hypertension, pre-existing CKD (SCr 
levels >2 mg/dL), hematocrit <30%, age over 70 years, car-
diac diseases, and recent myocardial infarction (<1 month). 
Iodixanol is the first choice for patients with myeloma or 
patients with monoclonal gammopathies, independent of 
additional risk factors.
Is There Any Biological and/or Clinical Evidence 
That Supports the Differential Impact of IOCM and 
LOCM on Renal Toxicity in Patients with Cancer? 
Does CM Viscosity Have a Role in Renal Toxicity?
Consistent evidence from cultured tubular cells has in-
dicated that LOCM has more severe cytotoxic effects than 
IOCM. In addition, in animal models, IOCM is associated 
with a lower induction of Nox4-dependent reactive oxygen 
species (ROS) generation. IOCM also exerts fewer vasocon-
striction effects than LOCM.
The role of viscosity in CI-AKI risk is still being debated. 
All CM, which are more viscous than plasma, and agents 
with increased osmolality that have lower viscosity may 
still lead to AKI.
Should the Renal Function of all Patients with Cancer 
be Assessed before the Administration of CM?
Renal function (SCr levels or GFR) should be assessed in 
all patients with cancer before the administration of CM to 
define the best strategy to prevent AKI.
Is the Serum Creatinine Level the Only Clinical 
Criterion Used to Define AKI or CM-Induced 
Toxicity?
The combination of markers of functional damage (el-
evation in Serum Creatinine [SCr] levels) and structural 
damage (biomarkers) guarantees more accurate identifi-
cation of patients with subclinical AKI or those at a higher 
risk of developing persistent kidney damage.
Does Radiation Exposure for Diagnostic Purposes 
Increase the Risk of Developing New Forms of 
Cancer in Patients with Pre-Existing Cancer?
The risk of malignancy from diagnostic radiation expo-
sure in adults is generally low. The uncertainty surround-
ing this issue should prompt the use of low-dose protocols 
and adequate technology. Clinicians should take precau-
tions with patients who have been exposed to 10 mSv for a 
year because these patients have an increased risk of devel-
oping new forms of cancer.
How Should CT Protocols be Optimized for 
Oncology Patients?
CT protocols should be personalized according to the 
patient, tumor characteristics and needs to minimize ra-
diation exposure and the amount of CM while maintain-
ing adequate image quality. CT-specific protocols (num-
ber of phases acquired and body regions to be scanned), 
including the adoption of modern techniques for dose re-
duction (Automatic Dose Modulation and iterative recon-
struction algorithms) should be implemented while con-
sidering tumour characteristics and different clinical set-
tings, as well as the diagnostic work-up and disease staging, 
evaluation of the response to treatment and long-term fol-
low-up.
How Should Contrast Enhancement be Optimized 
for Standard and Low-Dose Acquisition Protocols in 
Oncology Patients?
Adequate liver enhancement requires personalization 
of the amount of CM. The CM dose should be calcu-
lated according to mgI rather than volume. The CM 
dose should be defined according to total body weight 
(TBW) and, in patients with a BMI >25, to lean body 
weight. A range of 500–600 mgI per kg BW is considered 
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adequate for liver enhancement. Adequate enhance-
ment of hypervascular liver lesions requires a minimum 
iodine delivery rate of 1.2 gI/s using a standard acquisi-
tion protocol.
In Patients with Cancer, Does the Use of a Dimeric 
IOCM Permit Better Diagnostic Imaging in  
Low-Dose Procedures than Standard Protocols?
No evidence supports the superiority of a specific CM in 
patients with cancer. The use of IOCM should be preferred 
due to its higher safety profile and patient tolerance, par-
ticularly in intra-arterial injections. Similar trends, al-
though with weaker evidence, are observed for intravenous 
injections.
Discussion
The statements and recommendations appear in ital-
ics and are stated below. Each statement is discussed in a 
short paragraph reporting the current key evidence.
Statement 1
The incidence of AKI in patients with cancer ranges 
from 12 to 17%, and it is higher than the incidence observed 
in patients without cancer (5–8%). Risk factors include the 
type of cancer, comorbidities, co-treatment with FANS/fu-
rosemide, antibiotics, chemotherapy and CM administra-
tion. Among drugs commonly used for chemotherapy and 
targeted therapy, an increased risk of AKI has been docu-
mented in patients treated with bevacizumab, pemetrexed, 
cetuximab, ifosfamide and the platinum derivative cispla-
tin. Specific cancer locations (esophagus, kidney, liver, 
pancreas, craniopharyngeal duct, heart/mediastinum and 
uterus) and cancer types (lymphoma, leukemia, mixed 
lymphosarcoma, multiple myeloma) correlate with an in-
creased risk of AKI.
AKI, which was formerly called acute renal failure, is 
commonly defined as an abrupt decrease in renal func-
tion and clinically manifests as a reversible acute increase 
in nitrogen waste products that is determined by measur-
ing blood urea nitrogen and SCr levels over the course of 
hours to weeks (KDIGO; Table 1) [3].
Patients with cancer must be considered a population 
at high risk of developing AKI [4]. In a Danish popula-
tion including 37,267 cancer patients, the risk of AKI 
(defined as a >50% increase in SCr levels) was approxi-
mately 17.5% within 1 year of a cancer diagnosis and 
27% after 5 years [5]. The rate of AKI in hospitalized 
patients with cancer seems to be higher than the rate re-
ported for hospitalized patients without cancer (12 vs. 
5–8% respectively) [4, 6, 7]. Chertow et al. [7] evaluated 
the effects of AKI on the clinical outcomes and costs re-
lated to hospital stays for patients with cancer. They re-
ported a 4.7-fold increase in death, a 3-day increase in 
the length of the hospital stay, and a USD 42,671 in-
crease in costs for hospitalized patients. Consequently, 
AKI has a relevant clinical and economic impact that 
must be considered.
Numerous factors and patient characteristics contrib-
ute to the increased risk of developing AKI in this patient 
population [8]. The OR for developing AKI is significant-
ly higher for patients with diabetes (OR 1.89; 95% CI 
1.51–2.36), those receiving chemotherapy (OR 1.61; 95% 
CI 1.26–2.05), those given an intravenous injection of 
CM (OR 4.55; 95% CI 3.51–5.89), patients with hypona-
tremia (OR 1.97; 95% CI 1.57–2.47) and patients who use 
antibiotics (OR 1.52; 95% CI 1.15–2.02) [4]. Heart failure, 
a recent myocardial infarction (<1 month), hypertension, 
preexisting chronic kidney disease (CKD), and an age 
over 70 years must also be considered additional risk fac-
tors [9]. Moreover, patients with cancer originating in 
their oesophagus, kidney, liver, pancreas, craniopharyn-
geal duct, heart/mediastinum, or uterus and patients af-
fected by lymphoma, leukaemia, mixed lymphosarcoma 
or multiple myeloma are considered a very high risk pop-
ulation with a ≥15% probability of developing AKI [4].
Medications play a critical role. According to the Re-
nal Insufficiency and Anticancer Medications study [10], 
Table 1. CI-AKI definition. The 2007 guidelines of the AKIN de-
fined CI-AKI as an absolute change in the SCr levels of ≥0.3 mg/
dL after an i.v. injection of CM
Stage SCr levels Urine output
I 1.5–1.9 × baseline 
Or increase of ≥0.3 mg/dL 
(≥26.5 mmol/L)
<0.5 mL/kg/h for 6–12 h
II 2.0–2.9 × baseline <0.5 mL/kg/h for ≥12 h
III 3.0 × baseline
Or increase to ≥4.0 mg/dL 
(≥353.6 mmol/L)
Or initiation of RRT
Or decrease in eGFR to <35 mL/
min/1.73 m2 in patients <18 
years old
AKIN, acute kidney injury network; KDIGO, kidney disease 
improving global outcomes; RRT, renal replacement therapy.
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50–60% of cancer patients who are undergoing antineo-
plastic treatment develop a renal impairment. Patients 
with cancer are exposed to multiple nephrotoxic agents 
(cytotoxic drugs, antibiotics, analgesics and drugs for 
supportive therapy). Both cytotoxic and cytostatic drugs 
are characterized by a specific nephrotoxic effect (Table 
2). Ifosphamide and platinum agents (cisplatin and car-
boplatin) cause both glomerular and tubular damage. 
Cisplatin nephrotoxicity is the most common form of 
toxicity, occurring in 30–100% of children, and it typi-
cally causes glomerular impairment and tubulopathy, 
which clinically presents as magnesuria and hypomagne-
semia [10]. The incidence and severity of renal toxicity 
increases with repeated usage of cisplatin-based chemo-
therapy, and CI-AKI may subsequently become irrevers-
ible. Thus, cisplatin discontinuation is generally indicat-
ed in patients who present signs of progressive renal im-
pairment [11].
Some targeted agents may induce glomerular endothe-
lial cell swelling, vacuolization and detachment, as well as 
disruption of epithelial cell slit diaphragms [12]. Cetux-
imab induces hypomagnesemia resulting from a renal 
magnesium leak. Bevacizumab induces hypertension and 
kidney-specific injury, including proteinuria and AKI.
Statement 2
Iodate CM is a risk factor for AKI. The risk for AKI as-
sociated with CM (OR 4.55) is higher than the risk observed 
for other risk factors, such as diabetes, chemotherapy, hy-
ponatremia and antibiotic use. A short time span between 
chemotherapy administration and CM injection is associ-
ated with an increased risk of AKI.
Iodinated CM is frequently used for interventional 
and diagnostic procedures in patients with cancer. Intra-
arterial or intravenous injection of these agents increases 
patients’ risks of developing CI-AKI. Salahudeen et al. [4] 
showed that in hospitalized cancer patients, the OR for 
developing AKI is significantly higher for intravenous 
contrast injections (OR 4.55). Several factors contribute 
to the increased risk, including the type and volume of 
CM, frequency of contrast-enhanced imaging, comor-
bidities, underlying renal function and chemotherapies 
[3, 9, 13–15]. Hypertension and the combination of beva-
cizumab/irinotecan may be additional risk factors for CI-
AKI [8].
The effects of the administration of CM and chemo-
therapy within a short time have been widely investi-
gated. Exposure to CM within a week before cisplatin 
administration increased the risk of AKI by 2.56-fold 
[11]. Cicin et al. [8] reported an incidence of CI-AKI 
after CT in hospitalized oncology patients of 20%. 
Moreover, CI-AKI developed 4.5 times more frequent-
ly in patients with cancer who had undergone a CT 
within 45 days after their last chemotherapy treatment 
(p = 0.005), which was also considered an independent 
risk factor (p = 0.017). In patients with cancer who re-
quire CECT in an emergency setting, the OR of devel-
oping CI-AKI (increase in SCr levels of ≥0.5 mg/dL or 
≥25% within 48–72 h) was 4.09 (95% CI 1.34–12.56) in 
patients requiring serial examinations on consecutive 
days compared with patients who only received scans 
on 1 day [16].
Table 2. Kidney injuries associated with chemotherapeutic agents. 
from Perazzella et al. [12]
Renal vasculature 
Hemodynamic AKI (capillary leak syndrome) 
IL-2, denileukin diftitox 
Thrombotic microangiopathy 
Antiangiogenesis drugs (bevacizumab and tyrosine 
kinase inhibitors) 
Gemcitabine and cisplatin 
Mitomycin C and IFN 
Glomeruli
Minimal change disease 
IFN 
Pamidronate
Focal segmental glomerulosclerosis 
IFN 
Pamidronate 
Zoledronate (rare)
Tubulointerstitium
Acute tubular necrosis
Platinums, zoledronate, ifosfamide, and mithramycin
Pentostatin, imatinib, diaziquone, and pemetrexed
Tubulopathies
Fanconi syndrome
Cisplatin, ifosfamide, and azacitadine, diaziquone, 
imatinib, and pemetrexed
Salt wasting
Cisplatin and azacitadine
Magnesium wasting
Cisplatin, cetuximab, and panitumumab
Nephrogenic diabetes insipidus
Cisplatin, ifosfamide, and pemetrexed
Syndrome of inappropriate antidiuresis
Cyclophosphamide and vincristine
Acute interstitial nephritis
Sorafenib and sunitinib
Crystal nephropathy
Methotrexate
IFN, interferon.
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Statement 3
The use of CM with the lowest osmolarity is advisable, 
particularly in high-risk patients. Patients with cancer 
must be considered as a high-risk group, and IOCM should 
be considered the first choice, particularly if the patients 
are affected by at least one of the following conditions: in-
tra-arterial injection, diabetes mellitus, liver diseases, hy-
pertension, pre-existing CKD (SCr levels >2 mg/dL), he-
matocrit <30%, age over 70 years, cardiac diseases, and 
recent myocardial infarction (<1 month). Iodixanol is the 
first choice for patients with myeloma or patients with 
monoclonal gammopathies, independent of additional risk 
factors.
Evidence of the reduced incidence of CI-AKI in the 
general population and patients with cancer who have re-
ceived IOCM has emerged from several studies, includ-
ing systematic reviews and meta-analyses [3, 9, 14]. Dif-
ferent CM have been developed, each with their own 
pharmacological characteristics [17]. The most impor-
tant feature for determining the risk of CI-AKI seems to 
be the osmolality of the CM, and the risk is higher for 
agents with increased osmolality compared to that of 
IOCM [18].
For example, with intra-arterial administration, the 
relative risk of AKI following iso-osmolar iodixanol, 
compared with the risk associated with a CM with in-
creased osmolality, was 0.46 (95% CI 0.27–0.79; p = 0.004) 
using a CI-AKI definition based on absolute changes in 
SCr levels of ≥0.5 mg/dL [18]. As shown in the meta-anal-
ysis by Dong et al. [19] compared with LOCM, intra-ar-
terial administration of iodixanol significantly decreased 
the risk of CI-AKI (risk ratio 0.68; 95% CI 0.50–0.92; Z = 
2.47; p = 0.01) with no significant heterogeneity among 
studies (p = 0.14, I2 = 32.4%). 
To date, a single randomized, prospective, compara-
tive study of oncology patients with patients who have a 
very low risk of CI-AKI, which was defined as a glomeru-
lar filtration (GFR) rate >60 mL/min, has been conduct-
ed. The results from an interim analysis showed a lower 
incidence of AKI in patients who have received an intra-
venous injection of IOCM (0.5%) compared to iopromide 
(0.5 and 2.8% respectively) [20].
Intravenous administration of iodine-based contrast 
agent in patients with multiple myeloma complicated 
with monoclonal gammopathies is associated with a high 
risk of AKI. The risk is increased by comorbidities, such 
as CKD, hypercalcemia, diabetes, dehydration, and use of 
nephrotoxic drugs. According to the Preda study, the use 
of iodixanol appears to be safe in patients with monoclo-
nal gammopathies and an eGFR ≥60 mL/min/1.73 m2 
and does not seem to be an absolute contraindication to 
the intravenous administration of iso-osmolar iodine-
based contrast agent in patients with monoclonal gam-
mopathies [21]. Concerning intravenous administration, 
the Nguyen study, which enrolled patients with decreased 
renal function, showed an inferior incidence of CI-AKI 
in patients treated with iodixanol (8.5%) compared with 
the iopromide group (27.8%; p = 0.012) [22]. Based on the 
Wang study, all-cause mortality was higher (1.5- to 1.8-
fold) for patients in the CKD subgroup who received 
LOCM than for patients who received IOCM, with a clear 
trend towards significance, and LOCM was associated 
with higher odds (approximately 1.6-fold) of a long-term 
elevation of SCr level than IOCM when adjusted for in-
verse probability weights [23].
Several guidelines recommend that contrast agents 
with the lowest osmolality should be used and high-risk 
patients should be administered IOCM, regardless of the 
administration route [3, 9, 14]. The guidelines of ACCF 
and AHA recommend the use of IOCM as a strategy to 
prevent AKI in patients with stable ischaemic heart dis-
ease [24]. Based on the Onco-Nephrology Curriculum of 
the American Society of Nephrology, high-osmolar 
(>1,400 mOsm/kg) and low osmolar (600–800 mOsm/
kg) CM are associated with a higher incidence of AKI 
compared to IOCM (300 mOsm/kg). Preventive mea-
sures should be implemented in oncology patients with 
GFR <60 mL/min, including limiting contrast volume 
and using IOCM. 
Statement 4
Consistent evidence from cultured tubular cells has in-
dicated that LOCM has more severe cytotoxic effects than 
IOCM. In addition, in animal models, IOCM is associated 
with a lower induction of Nox4- dependent reactive oxygen 
species (ROS) generation. IOCM also exerts fewer vasocon-
striction effects than LOCM. The role of viscosity in CI-AKI 
risk is still being debated. All CM, which are more viscous 
than plasma, and agents with increased osmolality that 
have lower viscosity may still lead to AKI.
CM osmolality has been suggested to play a key role in 
determining renal toxicity, as documented by in vitro and 
in vivo models. LOCM have less severe nephrotoxic ef-
fects than high-osmolar ionic contrast media [18, 19]. In 
addition, in high-risk patients, the iso-osmolar dimer io-
dixanol is associated with fewer nephrotoxic effects than 
LOCM [25]. The combination of both ischaemic and che-
motoxic injury in the proximal tubules triggers a process 
called tubule glomerular feedback, which reduces filtra-
tion at the glomerulus level, increasing plasma concentra-
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tions of creatinine (Cr) approximately 24–48 h after a sig-
nificant reduction in filtration [26]. Iodinated CM is a 
water-soluble and freely filtered agent that does not injure 
the glomerulus. Therefore, haematuria is not observed. 
However, its water solubility allows for relatively easy re-
absorption by the proximal tubular cells, where it causes 
cellular damage [27]. Based on recent evidence, the mito-
chondria of damaged renal tubular cells release intracel-
lular catalytic or unbound iron, which serves as the cata-
lyst in the Haber-Weiss and Fenton reactions to drive 
oxidative stress and the production of the dangerous hy-
droxyl radicals [28]. The finding that LOCM exerts fewer 
nephrotoxic effects than high-osmolar ionic contrast me-
dia in vivo correlates with its reduced cytotoxic effects in 
vitro [29].
Netti et al. [30] investigated the effects of LOCM expo-
sure on NADPH-dependent ROS generation by tubular 
cells. Iohexol, iopamidol and iodixanol were assessed at 
equimolar iodine concentrations, and their effects on hu-
man renal proximal tubular cells were studied/moni-
tored/described (PTCs). Cytotoxicity, apoptosis and ne-
crosis were investigated. At angiographic concentrations, 
iodixanol induces fewer cytotoxic effects on cultured tu-
bular cells than iohexol and iopamidol and generates low-
er levels of Nox4-dependent ROS.
Other pharmacological characteristics of CM, such as 
viscosity, which is mainly related to the size rather than 
the number of particles, are not believed to have a clinical 
impact on CI-AKI risk, although this is still under debate. 
Two main aspects should be considered. First, CM viscos-
ity is related to temperature. As the temperature of a giv-
en CM increases, a concomitant decrease in its dynamic 
viscosity is observed. Therefore, warmed CM are less vis-
cous than room temperature CM. Second, all CM are 
more viscous than plasma. According to McCullough et 
al. [25], contrast agents with increased osmolality that 
have lower viscosity may still lead to AKI. However, Seeli-
ger et al. [31] suggested a relevant role for CM viscosity 
in the development of CI-AKI and that increased viscos-
ity compromises blood flow and oxygen supply to critical 
regions of the kidney. The compromised flow delays the 
tubule glomerular feedback, probably resulting from in-
creased tubular fluid viscosity, and impairs GFR. Al-
though various properties of iodinated contrast agents, 
such as osmolality, ionic strength, viscosity and iodine 
content, have been implicated in renal toxicity, osmolal-
ity is the principal factor [25, 32].
Once CM has been administered, its osmolality is a not 
modifiable characteristic. Conversely, the viscosity may 
change due to thixotropy, which is a time-dependent 
shear thinning property. Under static conditions, a given 
fluid will flow (become thin and less viscous) over time 
when it is shaken, agitated, or otherwise stressed (time-
dependent viscosity). It then takes a fixed time to return 
to a more viscous state. Some non-Newtonian pseudo-
plastic fluids show a time-dependent change in viscosity. 
The longer the fluid undergoes shear stress, the lower its 
viscosity. A thixotropic fluid is a fluid that requires a finite 
time to attain equilibrium viscosity when introduced to a 
step change in shear rate. When the CM mixes with the 
blood, the viscosity of CM attempts to establish equilib-
rium with the blood viscosity, but as long as it is in mo-
tion, the CM tends to be less viscous than blood.
Statement 5
Renal function (SCr levels or GFR) should be assessed in 
all patients with cancer before the administration of CM to 
define the best strategy to prevent AKI.
Precision medicine and personalized risk assessments 
should be implemented, particularly in patients with can-
cer. Based on the number of risk factors in this specific 
population, our recommendations are designed for a 
pragmatic approach that can be easily applied to patients 
in routine clinical practice. Therefore, we felt comfortable 
distinguishing 3 different clinical scenarios:
Ambulatory patients: In ambulatory patients, renal 
function should be assessed by measuring SCr levels 
(preferably enzymatic method) and calculating the en-
hanced GFR (eGFR; Table 3) within the 2 weeks prior to 
the CECT. 
When a patient with one of the following characteris-
tics (i.e., renal cancer, extensive liver parenchymal in-
volvement, multiple myeloma, or antineoplastic drug 
[bevacizumab and irinotecan] administration within the 
<45 days prior to CM injection) presents for treatment, 
the oncologist should obtain enzymatic creatinine mea-
surements and calculate the eGFR within one week of the 
CECT.
Hospitalized patients: In hospitalized patients, renal 
function should be assessed by measuring SCr levels 
(preferably using an enzymatic method) and the GFR on 
the day before the examination. Patients with a reduced 
eGFR and clinical manifestations of CKD should be con-
sidered at high risk of developing CI-AKI (in this case, 
acute or chronic). Even in the absence of clinically evident 
CKD, oncology patients should be considered at a higher 
risk of developing CI-AKI, particularly elderly patients.
Ideally, after CM administration, patients should be 
followed using renal function assessments within 48–72 h 
of CM administration.
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In a research setting, additional assessments of renal 
function in patients at higher risk who have normal 
baseline SCr levels can be performed using the Kidney 
Stress Test and by measuring the Renal Functional re-
serve. In patients undergoing chemotherapy or patients 
with other conditions associated with higher risks, the 
measurement of damaged biomarkers may contribute 
to assessments of ongoing kidney injury and thus the 
imaging examination should be postponed or re-con-
sidered.
Statement 6
The combination of markers of functional damage (el-
evation in SCr levels) and structural damage (biomarkers) 
guarantees more accurate identification of patients with 
subclinical AKI or those at a higher risk of developing per-
sistent kidney damage.
Elevated SCr levels are a delayed reflection of chang-
es in the GFR, and levels may not peak until 2–3 days 
after an insult [33]. Furthermore, SCr levels may be af-
fected by several non-renal factors, such as patient char-
acteristics (including muscle mass), drug therapies, fluid 
overload and laboratory conditions [34]. A growing 
concern is that the GFR may be sustained even over the 
course of injuries, since kidneys compensate for damage 
until approximately 50% of nephrons are lost. The clin-
ical significance of changes in SCr levels and GFR de-
pends on patients’ underlying renal function to a large 
extent. The same degree of kidney injury will have dif-
ferent implications for a patient with CKD compared to 
someone with a high baseline GFR, in whom the injury 
may produce no clinical symptoms [35]. To ensure that 
AKI is identified before the damage is severe enough to 
affect kidney function, alternative or additional mea-
sures of kidney injury are needed. Biomarkers of struc-
tural damage may help facilitate early AKI diagnosis and 
treatment initiation. Advances in this field have been 
made with the discovery and validation of cell-cycle ar-
rest biomarkers, such as tissue inhibitor of metallopro-
teinase 2 and insulin-like growth factor binding protein 
7 [36]. The combination of these biomarkers, which was 
measured by the approved NephroCheck test [36], ap-
pears to be highly predictive of the risk of moderate to 
severe AKI in the subsequent 24–48 h [37]. However, 
the NephroCheck test has not yet been validated as a 
prognostic test for CI-AKI. Several other biomarkers of 
kidney damage have also been characterized, including 
neutrophil gelatinase-associated lipocalin [38], kidney 
injury molecule 1 [39], and N-terminal pro-B-type na-
triuretic peptide [40]. Of these biomarkers, neutrophil 
gelatinase-associated lipocalin has shown the most 
promise as a diagnostic and prognostic tool for AKI. 
Biomarkers may also have a role in identifying patients 
at higher risk of enduring kidney damage or relapsing 
Table 3. Definition of GFR and eGFR
GFR
The GFR describes the flow rate of filtered fluid through the kidney. The creatinine clearance rate (CCr or CrCl) is the  volume of 
blood plasma that is cleared of creatinine per unit of time and is a useful measure for approximating the GFR. 
The GFR is equal to the clearance rate when any solute is freely filtered and is neither reabsorbed nor secreted by the  kidneys. 
Therefore, the measured rate is the quantity of the substance in the urine that originated from a calculable volume of blood. Relating 
this principle to the equation listed below, for the substance used, the product of the urine concentration and urine flow equals the 
mass of the substance excreted during the time in which the urine has been collected. This mass equals the mass filtered at the 
glomerulus because nothing is added in or removed from the nephron. Dividing this mass by the plasma concentration provides the 
volume of plasma through which the mass must have originated, and thus the  volume of plasma fluid that has entered Bowman’s 
capsule within the aforementioned period. The GFR is typically recorded in units of volume per time, for example, millilitres per 
minute mL/min and compared to the filtration fraction.
GFR = urine concentration × urine flow/plasma concentration.
eGFR
The eGFR is a calculation based on the results of a blood creatinine test and other variables, such as age, sex, and race 
(e.g., African-American, non-African American), depending on the equation used.
It is used to screen for and detect early kidney damage, to help diagnose CKD, and to monitor kidney status. 
The National Kidney Disease Education Program, American Society of Nephrology, and the National Kidney Foundation all 
recommend that an eGFR be calculated each time a creatinine blood test is performed. The creatinine test is frequently  requested as 
part of a routine comprehensive metabolic panel (CMP), a basic metabolic panel (BMP), or along with a blood urea nitrogen (BUN) 
test to evaluate the status of a person’s kidneys. 
Creatinine, along with eGFR, is often used to monitor people with known CKD and people with conditions such as diabetes and high 
blood pressure (hypertension) that may lead to kidney damage.
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kidney dysfunction, for whom the prognosis is poor 
compared with that of patients who experience early re-
versal and recovery from kidney injury.
We anticipate that a combination of markers of func-
tional damage (elevated SCr levels) and structural dam-
age (biomarkers) will provide clinicians the greatest op-
portunity to identify patients with subclinical AKI or pa-
tients with the highest risks of developing persistent 
kidney damage, which would allow for prompt interven-
tion and help preserve patient well-being over the long 
term. This combined approach would allow patients with 
either structural or functional damage alone and patients 
with both structural and functional damage to be identi-
fied [41]. 
Statement 7
The risk of malignancy from diagnostic radiation expo-
sure in adults is generally low. The uncertainty surround-
ing this issue should prompt the use of low-dose protocols 
and adequate technology. Clinicians should take precau-
tions with patients who have been exposed to 10 mSv for a 
year because these patients have an increased risk of devel-
oping new forms of cancer.
Although the individual risk estimated for radiation 
exposure from medical imaging is small, the concern over 
CT risks is related to the current rapid increase in CT us-
age. Small individual risks applied to an increasingly large 
population may result in a potential public health issue in 
the future.
Linet et al. [42] estimated that 29,000 future cancers 
will result from the 70 million CT scans performed in the 
United States in 2007. Approximately 0.6% of the cumu-
lative risk of cancer in a UK population up to 75 years of 
age is estimated to be attributed to diagnostic X-rays; the 
corresponding estimates in the United States and Japan 
are 0.9 and 3% respectively [43–46]. Moreover, approxi-
mately 2% of the 1.4 million cancers diagnosed annually 
in the United States may eventually be related to CT scans 
[42, 47, 48]. 
This effect is typically thought be stochastic and can 
occur at any level of radiation exposure, with the likeli-
hood increasing as the dose increases. The typical lag pe-
riod between radiation exposure and cancer diagnosis is 
at least 5 years, and in most cases, the lag may be 1 or 2 
decades or longer. 
Several evidences reported a definitive correlation be-
tween radiation induced cancer risk and dosage greater 
than 100 mSv, not common in medical imaging consider-
ing a single examination but frequently reached over a 
short time period in patients who undergo multiple CT 
examinations (e.g., CT in emergency setting, evaluation 
of complications after surgery, follow up for cancer pa-
tients) or complex interventional radiology and cardiol-
ogy procedures using fluoroscopy. 
A single CT examination of the abdomen and pelvis 
usually falls into a radiation dose range of approximately 
10 mSv. At this dose level, the radiation-induced risks are 
controversial and no relevant evidences are published at 
support. According to epidemiological data, an increased 
cancer risk is observed in the 10–100 mSv range, which is 
relevant to nuclear cardiac studies and many CT studies 
[49] (Table 4).
No data support an increased cancer risk at doses less 
than 10 mSv, which is the dose range relevant to radi-
ography and some nuclear medicine and CT studies 
[49]. 
Statement 8
CT protocols should be personalized according to the 
patient, tumor characteristics and needs to minimize ra-
diation exposure and the amount of CM while maintain-
ing adequate image quality. CT-specific protocols (num-
Table 4. Estimated risk of developing radiation-related cancer from repeat screens. From Lin et al. [49]
Study Screening test Frequency Age, years Radiation-related 
cancers (per 100,000 
screened)
Brenner [74] Lung CT (smokers) Annual 50–70 230 (males)
850 (females)
Kim et al. [75] Coronary artery calcification CT Annual 45–70 (males) 40 (males)
55–70 (females) 60 (females)
Berrington de Gonzalez et al. [76] CT colonography Every 5 years 50–70 150
Brenner and Elliston  [77] Whole body CT Annual 45–70 1,900
Yaffe and Mainprize [78] Mammography Annual at age <55 years 45–74 90 (females)
Biannual at age >55 years
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ber of phases acquired and body regions to be scanned), 
including the adoption of modern techniques for dose re-
duction (Automatic Dose Modulation and iterative re-
construction algorithms) should be implemented while 
considering tumour characteristics and different clinical 
settings, as well as the diagnostic work-up and disease 
staging, evaluation of the response to treatment and long-
term follow-up.
Multidetector CT (MDCT) is the most frequently used 
imaging method in clinical practice for the identification 
and characterization of lesions in oncology patients [50, 
51]. Currently, MDCT is considered a real volumetric 
technique with a spatial resolution of approximately 0.6 
mm [52]. The faster tube rotation (less than 0.3 s) reduc-
es the scan time and enables CT studies of the abdomen 
and pelvis within a single breath-hold. However, the in-
creased number of slices, the submillimetre collimation 
and the use of multiple dynamic post-contrast phases in 
a single examination may all contribute to increased ra-
diation exposure. Novel advances in dose reduction 
methods (e.g., Automatic Dose Modulation systems and 
iterative techniques for image reconstruction) are rou-
tinely implemented in modern scanners and have dra-
matically decreased radiation exposure. Despite these im-
provements, the scanning parameters and the number of 
phases acquired should be chosen carefully according to 
the clinical scenario.
Theoretically, a complete liver examination might in-
clude a pre-contrast scan, followed by a contrast-en-
hanced acquisition obtained during the arterial (some-
times split into early and late arterial phases), portal ve-
nous, and equilibrium phases. For several reasons, 
including radiation exposure, data explosion with com-
plex image viewing and storage, all 5 phases should not 
be acquired in each patient. Because solid evidence for 
this issue is not available, the selection and combination 
of acquisition phases depend on both the clinical ques-
tions and the radiologist’s experience. An overview of the 
most common clinical scenarios and protocols is present-
ed in Table 5.
A completely new concept of CT imaging has been in-
troduced with the advent of Dual Energy CT. Dual En-
ergy CT acquires datasets at different photon energy lev-
els in a single CT acquisition and provides information 
regarding the material composition of tissues based on 
differences in photon absorption. Moreover, using a dual 
energy post-processing software, a multiparametric ap-
proach to obtaining CT images is feasible. Virtual non-
contrast images avoid the need to acquire a pre-contrast 
scan, iodine maps improve the detection of small hyper-
vascular foci within a lesion, and monoenergetic levels 
reduce artefacts and increase conspicuity at low keV [53, 
54].
Another very promising acquisition protocol that does 
not require specific CT scans is the Split-bolus method. 
This innovative technique has the potential to reduce 
both the number of phases acquired and radiation expo-
sure by splitting the intravenous CM into 2 or 3 boluses 
and combining phases in a single scan. According to 
Scialpi et al. [55], this novel approach is an alternative to 
triphasic MDCT in the initial staging and follow-up of 
oncology patients.
Statement 9
Adequate liver enhancement requires personalization 
of the amount of CM. The CM dose should be calculated 
according to mgI rather than volume. The CM dose should 
be defined according to total body weight (TBW) and, in 
Table 5. CT acquisition protocols for the most common clinical scenarios in oncology patients
Pre-contrast 
scan
Arterial phase
(20 s)
Portal phase
(70 s)
Equilibrium 
phase (3 min)
Delayed phase 
(5–7 min)
Excretory
phase
Initial staging x© x x x¶ x∆ x®
Evaluation of response to treatment x© x£ x x¶
Long-term follow-up x© x€ x x¶¶ If needed after the arterial and portal phase. £ Only in patients with a hypervascular primary tumour (i.e., melanoma, renal cancer, NET, etc.). 
∆ If peritoneal involvement is suspected. ® In patients with renal, ureteral and bladder lesions. € In patients with suspected hypervascular lesions. © Avoidable if dual energy is available.
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patients with a BMI >25, to lean body weight. A range of 
500–600 mgI per kg BW is considered adequate for liver 
enhancement. Adequate enhancement of hypervascular 
liver lesions requires a minimum iodine delivery rate of 1.2 
gI/s using a standard acquisition protocol.
Vascular and liver parenchymal enhancements are 
generally affected by different kinetics. Vascular enhance-
ment is determined by the iodine dose delivered per unit 
of time (Iodine Delivery Rate [IDR]), whereas parenchy-
mal enhancement is influenced by the total iodine dose, 
which is strictly related to patient body size. The conspi-
cuity of liver lesions, particularly hypovascular lesions, 
depends on the degree of liver parenchyma enhancement 
[56, 57] and is directly correlated to the dose adminis-
tered. 
The most solid evidence for this topic is derived from 
2 historical studies. As shown in the studies by Bae [52] 
and Yamashita et al. [58], a dose of 500–600 mgI per kg 
TBW must be delivered to increase liver parenchymal 
attenuation during the portal phase of at least of 50–60 
UH [52, 58]. Currently, these doses are considered the 
minimum amount required for an accurate examina-
tion. The simultaneous occurrence of maximal en-
hancement of liver parenchyma with minimal enhance-
ment of the underlying hypovascular liver lesions im-
proves detection. However, most recent studies 
recommend tailoring the amount of CM according to 
patients’ lean body weight (LBW) [59, 60]. In particular, 
Kondo et al. [61] recommend injecting 750 mgI per kg 
of patients’ LBW to maximize the lesion detection rate. 
The rationale for this novel approach is related to the 
vascular characteristics of adipose tissue, which is poor-
ly perfused compared to parenchymal organs. There-
fore, the computation of LBW using a bioimpedance 
measuring device or through the James formula would 
provide a more accurate estimation of the amount of 
CM to inject without considering the useless contribu-
tion of poorly perfused adipose tissue, particularly in 
obese patients [59, 62]. 
In the case of hypervascular liver lesions, enhancement 
is directly proportional to IDR (gL/s). Radiologists can 
easily control the IDR by modifying the injection flow 
rate according to the iodine concentration of a given CM. 
As a general rule, if the acquisition of an arterial phase for 
body imaging is required, the IDR should not be less than 
1.2 gL/s, but a better IDR is 1.6 gL/s since it provides high-
er conspicuity [63, 64]. 
Another very important aspect to consider is the di-
rectly proportional relationship between low kV acquisi-
tion protocol and tissue contrast enhancement. Lowering 
the tube voltage during the CT acquisition protocol in-
creases tissue contrast enhancement. Iodine better ab-
sorbs X-ray photons at low energy because the X-rays are 
closer to the iodine k-edge. This principle has been wide-
ly used, mainly in CT-angiography, and it has potential 
advantages in clinical practice to reduce both radiation 
exposure and the amount of CM while maintaining opti-
mal tissue enhancement. As shown in the study by Bae 
[52], an increase in concentration by 1 mg of iodine per 
millilitre yields a contrast enhancement of 41.12 HU at 80 
kVp, 31.74 HU at 100 kVp, and 26.18 HU at 120 kVp. 
Moreover, based on the results of Botsikas et al. [65], the 
total amount of CM in gI could be reduced by 20% if low 
kVs are used. 
Statement 10
No evidence supports the superiority of a specific CM in 
patients with cancer. The use of IOCM should be preferred 
due to its higher safety profile and patient tolerance, par-
ticularly in intra-arterial injections. Similar trends, al-
though with weaker evidence, are observed for intravenous 
injections.
No clinical studies have directly investigated the pre-
ferred CM for oncology patients. To the best of our 
knowledge, none of the previously reported studies have 
compared the diagnostic accuracy of CT using different 
specific CM. However, concerning the safety profile, use-
ful information has been obtained from studies that as-
sessed clinical outcomes after an intravenous (i.v.) injec-
tion of iodinated CM. The results from several non-ran-
domized trials revealed significant clinical and laboratory 
improvements using IOCM. In previous clinical studies 
using intra-arterial administration, IOCM (iodixanol) 
was associated with less patient discomfort than LOCM 
[66–70]. 
Few studies have confirmed advantages of IOCM dur-
ing i.v. administration. Weiland et al. [71] recently per-
formed a randomized controlled trial aimed at compar-
ing the frequency and intensity of discomfort in patients 
who received i.v. injections of iodixanol and iopamidol 
for CECT of the abdomen and pelvis. Their results, which 
were obtained from approximately 300 patients, support 
the hypothesis that osmolality may be a key determinant 
of patient discomfort. Patients receiving iodixanol had 
significantly lower levels of moderate-to-severe or severe 
discomfort than patients receiving iopamidol, with heat 
being the major contributor. However, no significant dif-
ferences in the incidence of overall or contrast-related ad-
verse events were observed/reported between the 2 
groups. 
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Similar results from a larger sample of patients were 
obtained by Xiao et al. [72], and confirmed the better safe-
ty profile of IOCM. These authors reported a nearly 
threefold increase in the overall frequency of adverse 
events using iohexol compared to iodixanol (0.9 vs. 2.5%, 
p < 0.05). However, laboratory results did not show sig-
nificant differences across the study groups.
Gharekhanloo and Torabian [73] conducted a clinical 
trial to compare allergic adverse effects and contrast en-
hancement between iodixanol and iopromide. Iodixanol 
seems to produce significantly greater enhancement of 
the hepatic, aorta and portal veins than iopromide (p < 
0.01). Immediate reactions, such as nausea and vomiting, 
were less frequent in the iodixanol group (p = 0.01). Late 
skin reactions, such as rash, were more frequent in the 
iodixanol group (p < 0.01).
Conclusions
Based on current evidence, the number of patients 
whose cancer will be complicated by other chronic dis-
eases is expected to increase over the next few decades. 
A multidisciplinary approach to these patients will be 
necessary to evaluate the numerous risk factors that are 
frequently present in patients with cancer. The state-
ments discussed in this study address the clinical impli-
cations of numerous CT examinations, which provide 
clinicians with important and up-to-date information 
regarding methods to reduce complications in oncology 
patients.
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